Weekly Reports | Jan 17 2025
This story features NEUREN PHARMACEUTICALS LIMITED, and other companies. For more info SHARE ANALYSIS: NEU
For a more comprehensive preview of next week’s events, please refer to “The Monday Report”, published each Monday morning. For all economic data release dates, ex-div dates and times and other relevant information, please refer to the FNArena Calendar.
The week that was in Australian Finance:
-The Australian share market has shown mixed performance over the past week.
-In contrast to 2024, the rotation out of information technology stocks continued, with energy and mining coming into favour as the iron ore price edged higher in what is a seasonally robust period for Chinese steel production.
-Despite stronger-than-anticipated employment data, expectations of lower domestic interest rates, possibly with an RBA cut at the February 18 meeting, have boosted the real estate sector.
-Utilities were in favour, while Australian financials did not attract the same enthusiasm as US banks, which rallied following JPMorgan and Goldman Sachs’ quarterly earnings reports.
-Neuren Pharmaceuticals Ltd ((NEU)) saw its share price increase by 2.5% to $13.02 after its partner received Health Canada approval for a drug treating Rett syndrome.
-Baby Bunting ((BBN)) surged 13.9% after reporting strong sales growth.
-Myer Group ((MYR)) and Premier Investments ((PMV)) served up a disappointing 1H25 trading update sending shares down almost -30% and -17%, respectively.
-Next week marks the opening of a new chapter for the US, with President Trump’s second inauguration on Monday.
-US markets have adopted a more risk-off tone as speculation around the “known unknowns” – tariffs, tax cuts, the takeover of Greenland, and the Panama Canal, to name a few – move to centre stage for the next four years.
Have a great weekend, from your FNArena Team!
Corporate news in the week that was:
-The Western Australian government has approved Catalyst Metals’ ((CYL)) underground mining proposal for its Trident Gold project
-Telix Pharmaceuticals’ ((TLX)) revenue increased 46% quarter-on-quarter, with strong sales for its diagnostic radiopharmaceutical for prostate cancer imaging providing a boost
-Also; Telix is acquiring ImaginAb for -$73m
-MA Financial ((MAF)) launches $300m private credit trust on ASX
-Hells Angels boss Angelo Pandeli sues News Corp ((NWS)) for defamation
-The Fonterra Shareholders’ Fund ((FSF)) shares will cease trading on the Australian share market next month after its request to delist was approved
-Ingenia Communities Group ((INA)) has upgraded its guidance for FY25
-Macquarie Asset Management ((MQG)) invests up to $8.09bn in Applied Digital’s AI data centres
-Car Group ((CAR)) exits Australian tyre businesses, confirms FY25 guidance
-PWR Holdings’ ((PWH)) C&R Racing lands $8.9M US government order for cooling solutions
-Arafura Rare Earths ((ARU)) secures $200m from Australia to develop a mine and processing facility for critical minerals
-Mesoblast ((MSB)) raises $260m to launch Ryoncil in the US and support manufacturing and development
-Telstra ((TLS)) to spend $700m rolling out AI across its business
-Novonix ((NVX)) raises $32.3m to fund synthetic graphite production in the US
-Nine Entertainment ((NEC)) announces corporate restructuring
-Second suitor for AVJennings ((AVJ))
-Rio Tinto ((RIO)) and Glencore have reportedly discussed a merger that could create the largest mining company
-Pro Medicus ((PME)) announced yet another $33m deal with the University of Kentucky to expand its imaging platform in North America
-BHP Group ((BHP)) and Lundin acquired Filo Corp, forming a joint venture for copper projects in Argentina and Chile
Corporate Calendar
For a calendar of earnings result releases and a summary of earnings results to date, refer to FNArena’s Corporate Results Monitor (https://www.fnarena.com/index.php/reporting_season/)
Find out why FNArena subscribers like the service so much: “Your Feedback (Thank You)” – Warning this story contains unashamedly positive feedback on the service provided.
FNArena is proud about its track record and past achievements: Ten Years On
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: ARU - ARAFURA RARE EARTHS LIMITED
For more info SHARE ANALYSIS: AVJ - AVJENNINGS LIMITED
For more info SHARE ANALYSIS: BBN - BABY BUNTING GROUP LIMITED
For more info SHARE ANALYSIS: BHP - BHP GROUP LIMITED
For more info SHARE ANALYSIS: CAR - CAR GROUP LIMITED
For more info SHARE ANALYSIS: CYL - CATALYST METALS LIMITED
For more info SHARE ANALYSIS: FSF - FONTERRA SHAREHOLDERS FUND
For more info SHARE ANALYSIS: INA - INGENIA COMMUNITIES GROUP
For more info SHARE ANALYSIS: MAF - MA FINANCIAL GROUP LIMITED
For more info SHARE ANALYSIS: MQG - MACQUARIE GROUP LIMITED
For more info SHARE ANALYSIS: MSB - MESOBLAST LIMITED
For more info SHARE ANALYSIS: MYR - MYER HOLDINGS LIMITED
For more info SHARE ANALYSIS: NEC - NINE ENTERTAINMENT CO. HOLDINGS LIMITED
For more info SHARE ANALYSIS: NEU - NEUREN PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: NVX - NOVONIX LIMITED
For more info SHARE ANALYSIS: NWS - NEWS CORPORATION
For more info SHARE ANALYSIS: PME - PRO MEDICUS LIMITED
For more info SHARE ANALYSIS: PMV - PREMIER INVESTMENTS LIMITED
For more info SHARE ANALYSIS: PWH - PWR HOLDINGS LIMITED
For more info SHARE ANALYSIS: RIO - RIO TINTO LIMITED
For more info SHARE ANALYSIS: TLS - TELSTRA GROUP LIMITED
For more info SHARE ANALYSIS: TLX - TELIX PHARMACEUTICALS LIMITED